CheckMate 025 randomized Phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma

Bernard Escudier*, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer CheckMate 025 Investigators

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

165 Citations (Scopus)

Fingerprint

Dive into the research topics of 'CheckMate 025 randomized Phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences